Rindopepimut (CDX-110): Revision history

From Glioblastoma Treatments
Jump to navigationJump to search

Diff selection: Mark the radio buttons of the revisions to compare and hit enter or the button at the bottom.
Legend: (cur) = difference with latest revision, (prev) = difference with preceding revision, m = minor edit.

12 November 2024

31 March 2024

  • curprev 13:3113:31, 31 March 2024‎ Lazy talk contribs‎ 3,853 bytes +44‎ No edit summary
  • curprev 13:2313:23, 31 March 2024‎ Lazy talk contribs‎ 3,809 bytes +3,809‎ Created page with "{{TreatmentInfo |drug_name=Rindopepimut (CDX-110) |FDA_approval=Not FDA-approved; received Breakthrough Therapy designation for glioblastoma in Feb 2015 |used_for=EGFRvIII-positive Glioblastoma Multiforme (GBM) in newly diagnosed and recurrent cases |clinical_trial_phase=Phase III for newly diagnosed GBM was discontinued; Phase II for recurrent GBM showed promising results |common_side_effects=Transient, low-grade local reactions; overall well-tolerated |OS_without=Media..."
Retrieved from "http://glioblastomatreatments.wiki:80/index.php?title=Rindopepimut_(CDX-110)"